BreakingHAE
Haemonetics (HAE) Stock Soars 17% After an Analyst Rating Change
Haemonetics shares rose 17.5% as MT Newswires reported: Barrington Adjusts Price Target on Haemonetics to $140 From $118, Keeps Outperform Rating
Shares of Haemonetics Corporation (HAE) rose 17.5% to $119.47 in the session of Friday, October 9, on volume of 2.78M shares.
The move came as MT Newswires reported: Barrington Adjusts Price Target on Haemonetics to $140 From $118, Keeps Outperform Rating.
Other coverage:
- Strength Seen in Haemonetics (HAE): Can Its 17.5% Jump Turn into More Strength? (Zacks)
- Haemonetics (HAE) Jumped, What Is Behind The Move? (Simply Wall St.)
- Haemonetics shares jump as CSL sets 2027 rollout of plasma devices (Proactive)
What the GTA data shows
- Options: 352 calls vs. 312 puts traded (put/call 0.89), with $148K in call premium and $190K in puts.
- Market value: about $5.4B · Health Care.
Written by the GTA Research Desk from GTA Terminal data. Not investment advice.
FREE NEWSLETTER
Get stories like this in your inbox
The market's biggest stories each morning, plus what options traders, insiders and Congress are doing with their money. Free.